

Clover Health

Clover Health to Report Third Quarter 2025 Financial Results on November 4, 2025

October 7, 2025

WILMINGTON, Del., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today announced that it will release its financial results after the market closes on Tuesday, November 4, 2025. The Company's management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter.

Third Quarter 2025 Conference Webcast Details:

- **What:** Clover Health's Third Quarter 2025 Earnings Conference Call
- **When:** Tuesday, November 4, 2025, at 5:00 p.m. Eastern Time
- **Webcast:** To access the webcast, you may register at <https://clover-health-3q25-earnings-call.open-exchange.net/registration>.

A live and archived webcast of the conference call will also be accessible from the Investor Relations section of Clover Health's website at <https://investors.cloverhealth.com/> for 12 months.

About Clover Health:

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on [Medication Adherence](#), [Congestive Heart Failure](#), and [Chronic Obstructive Pulmonary Disease](#) as well as the earlier identification and management of [Diabetes](#) and [Chronic Kidney Disease](#).

Investor Relations:

Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:

press@cloverhealth.com